Flaxseed lignan complex, methods of using and compositions thereof

• US 10,449,224 B2
• Filed: 05/27/2008
• Issued: 10/22/2019
• Est. Priority Date: 05/25/2007
• Status: Active Grant

• Current Assignee: Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Original Assignee: Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Inventors: Christofidou-Solomidou, Melpo
• Primary Examiner(s): Clark, Amy L
• Application Number:
  US12/601,882
• Publication Number:
  US 20100239696A1
• Time in Patent Office: 4,165 Days
• Field of Search: None
• CPC Class Codes: A61K 36/55 Linaceae (Flax family), e.g. Linum

Abstract

This invention relates to methods and compositions for treating pathological lung conditions using whole-grain flaxseed or flaxseed lignans (isolated in form of the lignan precursor Secoisolariciresinol diglucoside (SDG) directly from whole-grain flaxseed or chemically synthesized directly into the mammalian, readily metabolizable forms, Enterodiol (ED) or Enterolactone (EL). Such pathological condition result from oxidative lung injury such as ischemia-reperfusion injury (related to lung transplantation), radiation fibrosis and cancer. Specifically, the invention is directed to the use of flaxseed lignans in the treatment of acute and chronic lung injury as well as cancer.

Claims

1. A method of reducing chronic lung fibrosis in a human subject comprising administering to a human subject having chronic lung fibrosis a composition comprising a therapeutically effective amount of a purified or chemically synthesized lignan, wherein said lignan is secoisolariciresinol diglucoside (SDG).

2. The method of claim 1, wherein the lung fibrosis is the result of acute lung injury.

3. The method of claim 1, wherein the chronic lung fibrosis is the result of an ischemia-reperfusion injury.

4. The method of claim 1, wherein the chronic lung fibrosis is the result of irradiation to the lung.

5. A method of reducing acute lung inflammation in a human subject comprising administering to a human subject having acute lung inflammation a composition comprising a therapeutically effective amount of a purified or chemically synthesized lignan, wherein said lignan is secoisolariciresinol diglucoside (SDG).